Literature DB >> 12705637

EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.

Ben Davidson1, Iris Goldberg, Aasmund Berner, Gunnar B Kristensen, Reuven Reich.   

Abstract

EMMPRIN is a member of the immunoglobulin superfamily of adhesion molecules and has a role in the activation of several matrix metalloproteinases (MMP). The objective of this study was to investigate the expression of EMMPRIN in effusions, primary and metastatic tumors of serous ovarian carcinoma patients, as well as to evaluate its association with clinicopathologic parameters and with MMP and integrin expression. Eighty effusions and eighty-three solid lesions were evaluated for expression of EMMPRIN mRNA using in situ hybridization (ISH). Protein expression was studied in 75 effusions and 55 biopsies using immunohistochemistry (IHC). EMMPRIN mRNA and protein were detected in carcinoma cells in 63/80 (79%) and 64/75 (85%) effusions, respectively. Expression was similar in peritoneal and pleural effusions. EMMPRIN was co-expressed with MMP-1 (P < 0.001), MMP-9 (P = 0.006) and the alphav (P = 0.013) and beta1 (P = 0.029) integrin subunits. In solid lesions, EMMPRIN localized most often to tumor cells (51/83 using ISH, 51/55 using IHC), but was also expressed in stromal and endothelial cells in approximately one third of the cases. EMMPRIN mRNA expression in tumor cells was most frequent in peritoneal metastases (P = 0.03). EMMPRIN expression in carcinoma cells of solid tumors showed an association with that of MMP-9 (P = 0.018), while labeling of stromal cells showed co-localization with the beta1 integrin subunit (P = 0.043). In survival analysis, EMMPRIN protein expression in stromal cells of primary tumors (P = 0.012) and in endothelial cells of all solid tumors (P = 0.023) correlated with poor survival. In conclusion, EMMPRIN is a novel prognostic marker in ovarian carcinoma, and is co-expressed with other metastasis-associated molecules in this malignancy. The identical phenotype of carcinoma cells in pleural and peritoneal effusions provides further evidence to our theory that cells at these sites share similar genotypic and phenotypic profiles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12705637     DOI: 10.1023/a:1022696012668

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  33 in total

1.  Complete one-hour immunocytochemistry based on capillary action.

Authors:  J A Reed; L J Manahan; C S Park; D J Brigati
Journal:  Biotechniques       Date:  1992-09       Impact factor: 1.993

2.  Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin.

Authors:  J J van den Oord; L Paemen; G Opdenakker; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

3.  Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.

Authors:  B Davidson; R Reich; I Goldberg; W H Gotlieb; J Kopolovic; A Berner; G Ben-Baruch; M Bryne; J M Nesland
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

4.  E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.

Authors:  B Davidson; A Berner; J M Nesland; B Risberg; H S Berner; C G Tropè; G B Kristensen; M Bryne; V Ann Florenes
Journal:  J Pathol       Date:  2000-12       Impact factor: 7.996

5.  Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.

Authors:  B Davidson; P Lazarovici; A Ezersky; J M Nesland; A Berner; B Risberg; C G Tropé; G B Kristensen; M Goscinski; G van de Putte; R Reich
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

6.  Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor.

Authors:  K Nabeshima; W S Lane; C Biswas
Journal:  Arch Biochem Biophys       Date:  1991-02-15       Impact factor: 4.013

7.  Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6.

Authors:  F Berditchevski; S Chang; J Bodorova; M E Hemler
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

8.  Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38.

Authors:  M Lim; T Martinez; D Jablons; R Cameron; H Guo; B Toole; J D Li; C Basbaum
Journal:  FEBS Lett       Date:  1998-12-11       Impact factor: 4.124

9.  Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers.

Authors:  K Muraoka; K Nabeshima; T Murayama; C Biswas; M Koono
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

10.  Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase.

Authors:  H Kataoka; R DeCastro; S Zucker; C Biswas
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

View more
  41 in total

1.  Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer.

Authors:  Yuan Yuan; Ning Shen; Shu-Yan Yang; Ling Zhao; Yong-Mei Guan
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

2.  Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma.

Authors:  Shaojun Zhu; Yanhong Li; Li Mi; Yang Zhang; Li Zhang; Li Gong; Xiujuan Han; Li Yao; Miao Lan; Zhinan Chen; Wei Zhang
Journal:  Dig Dis Sci       Date:  2011-07-26       Impact factor: 3.199

3.  EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer.

Authors:  Haining Zhu; Jun Zhao; Beibei Zhu; Joanne Collazo; Jozsef Gal; Ping Shi; Li Liu; Anna-Lena Ström; Xiaoning Lu; Richard O McCann; Michal Toborek; Natasha Kyprianou
Journal:  Prostate       Date:  2011-05-11       Impact factor: 4.104

4.  Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry.

Authors:  Wei Wu; Rongbing Wang; Hui Liu; Jie Peng; Damao Huang; Bo Li; Jingde Ruan
Journal:  Med Oncol       Date:  2008-07-30       Impact factor: 3.064

5.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Mutational analysis of Drosophila basigin function in the visual system.

Authors:  Michelle Munro; Yazan Akkam; Kathryn D Curtin
Journal:  Gene       Date:  2009-09-25       Impact factor: 3.688

7.  Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma.

Authors:  Vered Givant-Horwitz; Ben Davidson; Gregg van de Putte; Hiep Phuc Dong; Iris Goldberg; Sivan Amir; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 9.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

10.  Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma.

Authors:  Che Zhang; Ziliang Tu; Shiming Du; Yong Wang; Qibin Wang
Journal:  Pathol Oncol Res       Date:  2009-07-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.